Evaluating a prognostic tool for metastatic breast cancer care
Official title: Evaluation of the Acceptability, Appropriateness, and Feasibility/Usability of a Metastatic Breast-cancer Specific Prognostic Calculator Among Clinicians
Run by UNC Lineberger Comprehensive Cancer Center · NCT05440929 · Data updated 2026-11-12
This study is trying to see if a new tool that helps doctors predict outcomes for patients with metastatic breast cancer is easy to use and helpful for improving care.
Quick facts
| Study type | Observational |
|---|---|
| Sex | All |
| Enrollment | 15 (estimated) |
| Sponsor | UNC Lineberger Comprehensive Cancer Center Academic / other |
| Locations | 1 site (Chapel Hill, North Carolina) |
| Status | Recruiting |
| Started | July 7, 2022 |
| Main results expected | August 10, 2027 |
| Study ends | August 10, 2027 |
| Registry record updated | September 28, 2026 |
| Trial ID | NCT05440929 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates for this study are clinicians such as physicians, nurse practitioners, physician assistants, or nurse navigators with at least six months of experience in metastatic breast cancer care.
✕Probably not a fit
Patients who do not speak English may not benefit from this study due to language barriers.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This qualitative study involves semi-structured interviews with clinicians who care for patients with metastatic breast cancer to assess the acceptability, appropriateness, and usability of a specific prognostic calculator. The interviews will be conducted until thematic saturation is reached, with an estimated 10 participants. The data collected will be analyzed using themes guided by the Consolidated Framework for Implementation Research (CFIR). The goal is to inform an implementation strategy that enhances the use of this prognostic tool in clinical practice, ultimately aiding oncologists in identifying high-risk patients for better end-of-life care.
Why it matters
Potential benefit: If successful, this study could lead to improved identification of high-risk metastatic breast cancer patients, facilitating better end-of-life care.
How similar studies have gone: While this approach is focused on implementation science, similar studies have shown success in improving clinical tools' usability and acceptance in practice.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Verbal informed consent obtained to participate in the study. 2. Subject is willing and able to comply with study procedures based on the judgement of the investigator or protocol designee. 3. Physician, nurse practitioner, physician assistant, or nurse navigator 4. At least 6 months of experience in the clinical care of patients with metastatic breast cancer in the United States. Exclusion Criteria: * Non-English Speaking
Where it's running
-
University of North Carolina
Chapel Hill, North Carolina, United States Recruiting
Study contacts
- Principal investigator: Emily Ray, MD — University of North Carolina, Chapel Hill
- Study coordinator: Terri Eubanks, BSBA
- Email: teubanks@med.unc.edu
- Phone: 919-966-4530
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
PRT13722 in advanced HR+/HER2- breast cancer
This early study tests PRT13722, by itself and with standard therapies, to see if it is safe and has any signs of activity in adults with HR+/HER2- breast cancer who have progressed on prior treatments.
-
Personalized treatment after endocrine therapy failure in metastatic breast cancer
The study tests whether using a patient’s fresh tumor sample to try different drugs outside the body can help pick the next therapy for hormone receptor-positive, HER2-negative metastatic breast cancer that progressed on endocrine therapy.
-
SSGJ-612 plus a HER2-targeted ADC in HR-positive, HER2-low metastatic breast cancer
This phase II study tests whether adding SSGJ-612 to a HER2-targeted antibody-drug conjugate helps people with HR-positive, HER2-low or ultralow metastatic breast cancer.
-
SMP-656 in HER2-positive advanced breast cancer after ADC therapy
This trial tests whether SMP-656 given by IV every 3 weeks can help people with HER2-positive locally advanced or metastatic breast cancer who progressed after a HER2-targeted antibody-drug conjugate.
-
Entinostat with Pyrotinib and Endocrine Therapy in HER2-positive, HR-positive Advanced Breast Cancer after Trastuzumab Failure
This study tests whether adding entinostat to pyrotinib and hormone therapy is safe and helps patients with advanced HR+/HER2+ breast cancer who progressed after trastuzumab.
-
T-DXd–based therapy followed by targeted HER2 blockade and endocrine therapy in first-line HER2+ / HR+ metastatic breast cancer
This trial tests a sequence of therapies starting with T-DXd plus pertuzumab, then a maintenance phase with dual HER2 blockade, endocrine therapy, and CDK4/6 inhibitor, with a retreatment option of T-DXd if disease progresses.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.